title: Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy.
abstract: BACKGROUND
  Muscle pains with or without CK-elevation are among the most frequently observed side-effects in patients with hyperlipoproteinemia on various statins. The pathophysiological background, however, remains obscure.
  
  
  METHODS
  We examined isoprostane 8-epi-PGF2alpha, a marker of in-vivo oxidation injury, in plasma, serum and urine in these patients at baseline, when muscle problems manifested and different time intervals after withdrawing the respective statin. A healthy control group and a group of untreated patients with hyperlipoproteinemia were run as controls.
  
  
  RESULTS
  The majority of patients with muscular side-effects show elevated 8-epi-PGF2alpha in plasma and urine, whereas serum values were elevated only to a lesser extent. Stopping statin therapy or successfully changing to another member of this family of compounds resulted in a normalization of the values in all patients.
  
  
  CONCLUSIONS
  These findings indicate a significant involvement of oxidative injury in the muscular side-effects of statins in patients suffering from hyperlipoproteinemia.
authors.affiliation: Department of Nuclear Medicine, University of Vienna, Austria. Helmut.Sinzinger@akh-wien.ac.at
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
authors.forename: G
authors.initials: G
authors.lastname: Lupattelli
authors.forename: F
authors.initials: F
authors.lastname: Chehne
authors.forename: A
authors.initials: A
authors.lastname: Oguogho
authors.forename: C D
authors.initials: CD
authors.lastname: Furberg
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis*; D003402:Creatine Kinase / Q000097:blood*; D015237:Dinoprost / Q000031:analogs & derivatives*; D028441:F2-Isoprostanes / Q000097:blood* / Q000652:urine; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006951:Hyperlipoproteinemias / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000737:chemistry / Q000473:pathology*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D010146:Pain / Q000139:chemically induced*; D014662:Vasoconstrictor Agents / Q000097:blood* / Q000652:urine
chemical_list: D015415:Biomarkers; D028441:F2-Isoprostanes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014662:Vasoconstrictor Agents; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D003402:Creatine Kinase